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Abstract The imprinted H19 gene is highly expressed in human 
embryos, fetal tissues and is nearly completely shut off in adults. 
However, it is reexpressed in a number of tumors including blad- 
der carcinoma, demonstrating that HI9 RNA is an oncofetal 
RNA. Tumors induced by injection of bladder carcinoma cell lines 
express H19 in contrast o the cells before injection. These obser- 
vations support the notion of a positive correlation between HI9 
expression and bladder carcinoma. Loss of imprinting of H19 and 
IGF-2 was observed in samples of human bladder carcinoma. 
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1. Introduction 
The human H19 gene is a paternally imprinted, maternally 
expressed, gene. It is transcribed by RNA polymerase II, its 
transcripts are processed and transported to the cytoplasm but 
are not associated with ribosomes and not translated [1]. The 
function of the HI9 RNA is unknown. However, non-trans- 
lated RNAs may act as riboregulators. These include the H19 
RNA, the XIST gene product [2], IPW gene product [3] the 
enod 40 RNA [4] and RNA sequences beyond the termination 
codon of muscle specific mRNAs as in tropomyosin mRNA [5]. 
The relative few genes known to be imprinted tend to appear 
in clusters in certain chromosomal regions. The H19 gene in the 
human is located on the chromosome 1 lpl 5.5 in close physical 
proximity to the reciprocally imprinted IGF-2 gene [6]. IGF-2 
is a potent mitogene and is highly expressed in several tumors 
[7]. Several imprinted genes are clustered on human chromo- 
some 15 in an area critical for the Prader-Willi and Angelman 
syndromes [8]. 
The human H 19 gene is highly expressed uring pregnancy 
in the extraembryonic t ssues (placenta) in the embryo proper 
and in several fetal tissues, including the bladder [9]. Its expres- 
sion is nearly completely shut off postnatally. A noteworthy 
exception is the uteral endometrium of the adult female which 
expresses H19, the highest expression is during the secretory 
phase of the menstrual cycle [10]. 
The H 19 gene is reactivated during the development of some 
tumors which express the HI9 gene during embryogenesis and 
fetal life. H19 was found to be expressed in embryonic tumors 
like Wilm's tumor, rhabdornyosarcoma and hepatoblastoma 
[11] in trophoblastic tumors [12], testicular germ cell tumors 
[13], lung tumors [14] and in bladder carcinoma [15]. In all these 
tumors, except bladder carcinoma, loss of imprinting was re- 
ported. In analogy to oncofetal proteins uch as c~-feto-protein 
and carcino embryonic antigen (CEA) the H19 gene product 
can be considered an oncofetal RNA [16]. Actually the H19 
gene in the mouse was discovered as a gene under coordinate 
regulation with the ~-feto-protein in the liver [17]. Very little is 
known about a possible functional relationship between H19 
expression and tumorigenesis. It has been suggested that H19 
acts as a tumor suppressor gene but the above-mentioned find- 
ings do not support his proposal. 
The purpose of the experiments described in this paper is to 
provide new data concerning the relationship between H19 
expression and the loss of imprinting of H19 and IGF-2 in 
bladder cancer. 
2. Materials and methods 
2.1. Cell culture 
Bladder carcinoma cell lines HT-1376; UM-UC-3 and T24P were 
obtained from the American Type Culture Collection (ATCC), E J28 
cell line was obtained from the German Cancer Research Centre, Hei- 
delberg, Germany. C-2, a myoblast mouse cell line was kindly provided 
by Prof. David Jaffe, Dept. of Cell Biology, Weizmann Institute of 
Science, Rehovot, Israel. 
The medium used was DMEM.F12 (1 : 1) containing 10% fetal calf 
serum (Beit Haemek, Israel) 25 mM HEPES pH 7.4; penicillin (180 
units/ml), streptomycin (100 ¢tg/ml) and amphotericin B (0.2/lg/ml). 
All cultures were maintained inpolystyrene culture dishes (NUNC) 
and were transferred every 4 days by treatment with 0.05% trypsin- 
EDTA solution (Beit Haemek, Israel). 
2.2. Animals 
12 female CD-1 athymic nude (Nu/Nu) mice were used for the present 
study. At 50 days of age they were divided into 4 groups of 3 mice each. 
*Corresponding author. Fax: (972) (2) 61-0250. 
Abbreviations: IGF-2, insulin-like growth factor II gene; IPW, im- 
printed gene in the Prader-Willi syndrome r gion; GAPDH, glyceralde- 
hyde-3-phosphate dehydrogenase. 
2.3. Experimental design 
Cells from the cell lines UM-UC-3; T24P; HT-1376 and EJ28 were 
suspended in culture medium without serum (5 x 106 cells/ml) and in- 
jected into mice of groups 1 to 4, respectively. Each nude mouse re- 
ceived two bilaterally subcutaneous injections inthe dorsal flank region 
(1 x 106 cells/site). The tumors formed were isolated after they reached 
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the size of 1 cm diameter. Portions of the tumors were either preserved 
at -80°C for RNA extractions or fixed in formalin for histological 
examination and in situ hybridization, or kept in saline until isolation 
of tumor cells. Tumor cells were recovered as in [18] and maintained 
as described above. 
2.4. In situ hybridization 
The preparation of H 19 antisense riboprobe and the in situ hybridi- 
zation were performed as previously described by us [12]. 
2.5. Iso&tion of RNA and DNA 
Total cellular RNA was isolated from tissue by the guanidinium- 
thiocyanate procedure and from the cells by guanidium phenol chloro- 
form method [19]. DNA was isolated as described in [20]. 
2.6. RT-PCR analysis 
For synthesis of cDNAs, random hexamer primers (Boehringer, 
Mannheim, Germany) were used to initiate reverse transcription of 0.2 
pg total RNA with 50 units M-MLV Reverse Transcriptase (Gibco 
BRL). PCR amplification reactions for the genes investigated were 
performed in a Mini-Cycler (MJ Research, Watertown, MA, USA) in 
50 pl volume using Taq DNA polymerase and buffer (Boehringer, 
Mannheim, Germany). 
The primer sequences, number of cycles and conditions for amplifica- 
tions of cDNA of the H 19 gene were as described in [21]. The amplifi- 
cation of GAPDH cDNA was performed using GAPDH primers 
(Stratagene, La Jolla, CA, USA) according to the manufacturer's in-
structions, for 24 cycles. 
35 cycles of amplification of IGF-2 cDNA were carried out as de- 
scribed in [22]. 
Oligonucleotide primer sequence for PCR of Ha-ras-I were TGA- 
CGGAATATAAGCTGGTG (upstream) and GTACTGGTGGATG- 
TCCTCAA (downstream). The PCR conditions were an initial denatu- 
ration of 3 min and subsequent denaturation for 1 rain at 94°C, anneal- 
ing for 1 min at 60°C and extension for 1 min at 75°C (30 cycles) 
followed by 5 min final extensions at 75 ° C. 
Aliquots of 10 ,ul of the amplification products were separated on 2% 
agarose gels and visualized by ethidium bromide staining. 
Only those samples of RNA that gave completely negative results in 
PCR without reverse transcriptase were further analyzed. In addition, 
amplification of H 19 from DNA produced a larger product han ampli- 
fication from mRNA because of the presence of 2 introns in the compa- 
rable DNA sequence. 
2. 7. Analysis" of tissues for mono- or bi-allelic expression of H19 and 
IGF-2 
Tumor tissues were collected from patients with bladder carcinoma. 
DNA and reverse transcribed total RNA from each tissue was analy- 
sed by RFLP assay using the polymerase chain reaction and RsaI 
polymorphism in the HI9 gene, as described in [21] and an ApaI poly- 
morphism in IGF-2 as described in [22]. 
3. Results 
3.1. Mono- and bi-allelic expression of  i l l 9  and IGF-2 in human 
bladder carcinoma 
As it has been shown recently a high level of i l l 9  transcripts 
can be detected in the fetal urinary bladder [15]. Normal adult 
urothelium and low grade, non-invasive transitional cell blad- 
der carcinomas do not express H19, but in grade II and III 
bladder carcinomas, invasive transitional cell carcinomas, and 
in situ bladder carcinomas, reactivation of H 19 expression was 
demonstrated. H19 was proposed as a tumor marker for the 
progression to more malignant stages in bladder cancer [15]. 
As loss of imprinting is frequently observed in embryonal 
tumors [23], the allelic mode of the expression of H19 and 
IGF-2 was investigated. 
Out of 12 bladder carcinoma biopsies, 4 were informative as 
they showed RsaI restriction polymorphism in the H19 gene. 
Two showed ApaI restriction polymorphism in the IGF-2 gene 
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Fig. 1. Allelic mode of H19 expression in two out of four cases of 
bladder carcinoma, showing poymorphism in the H19 gene: lanes 
a = genomic DNA PCR products restricted with RsaI; lanes b = RT- 
PCR products before and lanes c = after restriction with RsaI, de- 
monstrating monoallelic expression i tumor 1 and bi-allelic expression 
in tumor 2. Lane M = molecular weight marker VI (Boehringer- 
Mannheim). The size of the DNA (bp) is indicated. 
and it is of interest o note that these two cases belonged to the 
group of four which were heterozygous for the H19 gene. In 
two of the four H19 informative tumors bi-allelic expression 
was observed, and in one of them IGF-2 expression too was 
bi-allelic (Figs. 1 and 2, patient 2). In the remaining two H19 
informative cases H19 expression was mono-allelic, in one of 
them the IGF-2 expression was also mono-allelic (Figs. 1 and 
2, patient 1). 
3.2. H19 expression in bladder carcinoma derived cell lines" 
RNA from four human bladder cancer derived cell lines were 
examined by Northern blot hybridization in order to establish 
the level of H 19 and IGF-2 expression during in vitro culturing. 
In three of them no expression of either H19 and IGF-2 could 
be detected (T24P; UM-UC-3; EJ 28) while in the HT-1376 cell 
line low levels of both H 19 and IGF-2 transcripts were present 
(Northern blot data, not shown). 
3.3. Tumor Jormation in nude mice, H19 and IGF-2 transcript 
levels in the xenograft 
In order to investigate a possible correlation between the H 19 
and IGF-2 RNA levels and tumorigenesis induced by cells 
derived from bladder carcinoma, cells from these four bladder 
cancer cell lines were injected subcutaneously into nude mice. 
Tumors with a diameter of approximately 1 cm were observed 
after 3 weeks (UM-UC-3) or 5-6 weeks (T24P; E J28; HT-1376). 
We used RT-PCR to compare the level of H19 and IGF-2 
transcripts in the cells before injection to that in the tumors and 
in the cells derived from these tumors and cultured in vitro for 
3 passages. In the four bladder cancer cell lines a recurrent and 
consistent pattern in the relationship between H19 expression 
and tumorigenesis was obvious. Expression of the H19 gene 
was observed in tumors induced by cells with no detectable H 19 
transcript content before injection (Fig. 3A - lanes 1 and 2). 
The appearance of H19 RNA was restricted to the tumor for- 
mation process since after 3 passages of in vitro culturing of 
cells isolated from the tumor produced in nude mice, the H19 
RNA level had decreased below the level of detection as in the 
cells before injection (Fig. 3A, lane 3). In order to investigate 
if this phenomenon is limited to the H19 gene we investigated 
additional genes for the following reasons. IGF-2 is a reciprocal 
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imprinted gene physically close to H19. The Ha-ras-1 gene 
expression because its expression is frequently increased in 
bladder carcinoma nd the gene is located physically close to 
the H19 and IGF-2 genes on chromosome 1 lp15.5 [24] and the 
GAPDH gene, because it is a housekeeping gene which is ex- 
pressed in every cell. The phenomenon described above (Fig. 
3A) is specific for the H19 gene. From the data in Fig. 3B it is 
very clear that a consistent correlation between IGF-2 expres- 
sion and tumorigeneity could not be observed. In total we 
determined the expression of H19 and IGF-2 genes in ten tu- 
mors and all of them confirmed the above mentioned conclu- 
sions. Also no changes in the expression of the Ha-ras-1 and 
the GAP-DH genes during tumorigenesis were observed (Fig. 
3C,D). 
In order to rule out the possibility that the RT-PCR product 
in the xenograft tumors is due to mouse H19 RNA, we per- 
formed RT-PCR with total RNA isolated from the C-2 myo- 
blast mouse cell line, known to express the H19 gene [25]. No 
RT-PCR product was detected (Fig. 3, lane C-2). 
The appearance of HI9 RNA in the induced tumors may be 
accompanied by a loss of H19 imprinting. However the allelic 
pattern of the H 19 expression i cells of the bladder carcinoma 
derived cell lines and in the tumors induced by them was not 
determined because RsaI polymorphism was absent in the cell 
lines used in the experiments. 
3.4. Localisation of i l l9 transcripts in the xenograft tumor 
We further examined the xenograft tumor tissue, by in situ 
hybridization, in order to determine whether all tumor cells 
express increased levels of HI9, or whether this phenomenon 
is restricted to certain cells only. 
In the xenograft tumor sheets of pleomorphic cells are seen 
(Fig. 4A) and HI9 is expressed in a number of small clusters 
and in single cells (Fig. 4B). This pattern of distribution is very 
similar to that observed in human bladder carcinoma in vivo 
[15]. 
4. Discussion 
It has been claimed that the reciprocal imprinted genes H19 
and IGF-2 are involved in the pathogenesis of embryonal tu- 
mors associated with the Beckwith-Wiedemann Syndrome [11] 
and other tumors such as testicular germ cell tumors [13] and 
lung cancer [14]. 
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Fig. 2. Allelic mode of IGF-II expression i two cases of bladder with 
Apal restriction polymorphism. Lanes a = RT-PCR products before 
and lanes b = after restriction with Apal (the cases represented are 
identical to those in Fig. 1). 
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Fig. 3. Expression of H19, IGF-2, Ha-ras-1 and GAPDH in four blad- 
der carcinoma cell ines and in tumors induced by them. Lanes 1 = cells 
before injection; Lanes 2 = tumors induced in nude mice; lanes 3 = cells 
derived from these tumors. Content of H19 (A); IGF-2 (B); Ha-ras-1 
(C) and GAPDH (D) RNA determined by RT-PCR as described in 
section 2. Lane M = DNA molecular-weight marker V1 (Boehringer- 
Mannheim). Lane C-2 = RT-PCR with total RNA from mouse myo- 
blast cell line C-2. 
In many cases Wilm's tumor is accompanied bythe maternal 
loss of chromosome 11 p 15.5 and frequently paternal disomy of 
this chromosomal rea was established [23]. These and similar 
findings formed the basis for the proposal that the H19 gene 
is a tumor suppressor gene. Further evidence for this proposal 
was provided by experiments carried out by Hao et al. [26] who 
introduced a construct expressing the H 19 gene under the con- 
trol of a metallothionein promoter into embryonal tumor cell 
lines. The transfected cells showed growth retardation but is 
noteworthy that in several of these cell lines the growth retarda- 
tion occurred in cells with prominent structural changes. Sup- 
pression of tumorigeneity was shown for one of these cell lines. 
However, we have recently pointed out that in contradiction to
its proposed tumor suppressor role, the H19 gene, is expressed 
in human bladder carcinoma of adults while the normal bladder 
tissue does not express the H19 gene [15]. 
We have further investigated the connection between H19 
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Fig. 4. Pattern of H19 RNA distribution i  tumors induced by UM- 
UC-3 cells in nude mice. In situ hybridization with H19 [3SS]antisense 
RNA heamatoxylin-eosin as a counter stain. (A) Brightfield (x 185); 
(B) the same as (A), but darkfield. 
expression and tumorigenesis u ing cell lines from two different 
sources, a cell line derived from choriocarcinoma (JEG-3) and 
cell lines derived from human bladder carcinoma s described 
here. 
H19 is expressed in cells of the choriocarcinoma derived cell 
line JEG-3. The level of the H19 transcripts in tumors formed 
after their injection into nude mice is 3-5 fold higher than in 
the original cells. The cells isolated from these tumors and 
cultured in vitro maintained the high level of H19 expression. 
We interpreted these results by assuming that cells with a rela- 
tively high level of H19 expression were selected during the 
process of tumorigenesis. In situ hybridization of the cells be- 
fore injection and of the tumor with H19 antisense RNA sup- 
ported this assumption [27]. 
No or very low expression of H19 was detected in the cells 
of four human bladder carcinoma cell lines in sharp contrast 
to the tumors induced by them in nude mice. However, cells 
isolated from these tumors had already lost their ability to 
express H19 after 3 passages of in vitro culture (Fig. 3A). 
This observation excludes the possibility that the increase in 
the H19 RNA level in the tumor is due to the clonal expansion 
of a few cells in the tumor cell lines which express H19 at a 
comparatively high level. The spatial distribution pattern of the 
H19 expression i  the xenograft (Fig. 4) supports this conclu- 
sion. It may, however, strongly indicate that H19 expression is
restricted to bladder cancer cells at certain stages of tumor 
progression only, as seems to be the case according to our 
findings in bladder carcinoma in vivo [15]. 
The relationship between H19 expression and the develop- 
ment of tumors induced in nude mice by bladder carcinoma cell 
lines described here shows striking similarities to the process of 
tumorigenesis of bladder carcinoma in vivo. Human bladder 
carcinoma develops in the adult from bladder mucosa cells 
which have since long lost their ability to express the HI9 gene, 
but H19 expression is activated uring carcinogenesis of blad- 
der carcinoma in vivo and during tumorigenesis induced by 
H 19 non-expressing bladder carcinoma cells in nude mice. Also 
in both cases expression is likely limited to cells at certain stages 
of tumorigenesis only. 
The very significant increase in the H19 transcript level dur- 
ing the process of tumorigenesis in vivo [15] and in vitro (in the 
nude mice as described above) may be the result of transcrip- 
tional activation and/or increase in the stabilization of the 
RNA. Also loss of imprinting of the gene, allowing transcrip- 
tion from two alleles, may be involved. The results described 
here clearly demonstrate hat the loss of H19 imprinting can 
occur during the development of human bladder carcinoma in 
vivo but it cannot be solely responsible for the increase in the 
level of H19 transcripts because an increase is also detected in 
tumors expressing HI9 in the mono-allelic mode (Fig. 1, lanes 
b). Also the loss of imprinting of the HI9 and IGF-2 genes is 
not obligatory for the development of bladder carcinoma (Figs. 
1 and 2). However, the possibility exists that biallelic expression 
of the H19 gene and/or the IGF-2 gene is a hallmark of those 
cells which are in advanced stages of tumorigenesis. In one of 
the tumors, both H19 and IGF-2 were bi-allelicly expressed, 
indicating uncoupling of i l l9  and IGF-2 expression i an adult 
tumor. A similar finding was recently reported in a case of 
juvenile hepatoblastoma [28]. 
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